Source comparison
IGF-1 LR3 Alternative to HGH Injections: Comparison
Before selecting between IGF-1 LR3 and HGH for research applications, understanding the practical differences in administration, mechanism, and response kinetics is essential. The table below compares key protocol variables across both peptides. Half-Life ~3 h
This comparison does not assign a generated winner or score.
- Before selecting between IGF-1 LR3 and HGH for research applications, understanding the practical differences in administration, mechanism, and response kinetics is essential. The table below compares key protocol variables across both peptides.
- Half-Life
- ~3 hours
- 20–30 hours
- LR3's extended half-life allows once-daily dosing and sustained receptor activation. HGH requires split dosing to maintain anabolic signaling
- Mechanism
- Binds GH receptors in liver → stimulates hepatic IGF-1 synthesis + direct GHR effects in adipose/cartilage
- Directly activates IGF-1 receptors in target tissues. Bypasses hepatic conversion step
- HGH produces both IGF-1-mediated and GHR-direct effects; LR3 is purely IGF-1 receptor activation
- Typical Dosing
- 2–6 IU daily, split into 2 injections
- 20–80 mcg daily, single injection
- Microgram dosing reflects high potency due to reduced IGFBP binding. Effective tissue concentration stays elevated longer
- Time to Effect
- 8–12 hours (delayed hepatic IGF-1 synthesis)
- 2–4 hours (direct receptor activation)
- LR3 produces acute anabolic signaling; HGH's effects accumulate over days as hepatic IGF-1 rises
- Cycle Duration
- 3–6 months (steady-state IGF-1 requires weeks)
- 4–6 weeks (receptor saturation occurs rapidly)
- Shorter LR3 cycles with structured washouts often yield more consistent results than continuous use
- Metabolic Effect
- Increases lipolysis, may induce insulin resistance
- Enhances insulin sensitivity, less pronounced lipolytic effect
- GHR-mediated glucose metabolism shift explains why HGH raises insulin resistance. LR3 typically improves it